Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Cash (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Change in Cash for 6 consecutive years, with -$8.5 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 69.83% to -$8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$41.1 million through Dec 2025, down 104.88% year-over-year, with the annual reading at -$41.1 million for FY2025, 104.88% down from the prior year.
  • Change in Cash for Q4 2025 was -$8.5 million at Relay Therapeutics, up from -$22.4 million in the prior quarter.
  • The five-year high for Change in Cash was $246.9 million in Q3 2022, with the low at -$202.8 million in Q4 2022.
  • Average Change in Cash over 5 years is -$18.2 million, with a median of -$10.1 million recorded in 2022.
  • Peak annual rise in Change in Cash hit 883.58% in 2022, while the deepest fall reached 1131.23% in 2022.
  • Over 5 years, Change in Cash stood at $51.6 million in 2021, then crashed by 493.42% to -$202.8 million in 2022, then surged by 96.26% to -$7.6 million in 2023, then crashed by 269.73% to -$28.1 million in 2024, then surged by 69.83% to -$8.5 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$8.5 million, -$22.4 million, and $20.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.